Business Analyst商业分析师

About WuXi XDC WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK) is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. WuXi XDC has been successful in bringing multiple ADC projects to the Investigational New Drug (IND) filing stage in 15 months or less, nearly cutting in half the traditional development timeline. As of June 2023, 110 on-going integrated projects are under development at WuXi XDC, including 47 post-IND bioconjugate projects, among which 16 projects are in phase II/III. For more information about WuXi XDC, please visit: https://wuxixdc.comResponsibilitiesPartner with the business development, proposals teams, project management and CMC team to analyze project information.Serve as the subject matter expert for business data, translating raw data into actionable business intelligencePresent findings and recommendations clearly and persuasively to senior leadership to inform strategic decision-makingDevelop and maintain dashboards and reports to track key commercial metricsConduct end-to-end analysis of critical business processes (e.g., from RFI ,client proposal to contract) to identify bottlenecks, and improve cycle timesQualificationsMasters and above in business analysis, computer science, data science life science or a related field.More than 2 years of experience as a business analyst, systems analyst, or similar roleExperience within the pharmaceutical, biotech, or CDMO industry is essential.More than 2 years of experience as a business analyst, systems analyst, or similar roleExperience within the pharmaceutical, biotech, or CDMO industry is essential.Fluent in Chinese and English